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ABSTRACT
Background: Protein ingestion increases muscle protein synthesis
rates. However, limited data are currently available on the effects
of branched-chain amino acid (BCAA) and branched-chain ketoacid
(BCKA) ingestion on postprandial muscle protein synthesis rates.
Objective: The aim of this study was to compare the impact of
ingesting 6 g BCAA, 6 g BCKA, and 30 g milk protein (MILK)
on the postprandial rise in circulating amino acid concentrations and
subsequent myofibrillar protein synthesis rates in older males.
Methods: In a parallel design, 45 older males (age: 71 ± 1 y;
BMI: 25.4 ± 0.8 kg/m2) were randomly assigned to ingest a drink
containing 6 g BCAA, 6 g BCKA, or 30 g MILK. Basal and
postprandial myofibrillar protein synthesis rates were assessed by
primed continuous l-[ring-13C6]phenylalanine infusions with the
collection of blood samples and muscle biopsies.
Results: Plasma BCAA concentrations increased following test
drink ingestion in all groups, with greater increases in the BCAA and
MILK groups compared with the BCKA group (P < 0.05). Plasma
BCKA concentrations increased following test drink ingestion in
all groups, with greater increases in the BCKA group compared
with the BCAA and MILK groups (P < 0.05). Ingestion of MILK,
BCAA, and BCKA significantly increased early myofibrillar protein
synthesis rates (0–2 h) above basal rates (from 0.020 ± 0.002%/h
to 0.042 ± 0.004%/h, 0.022 ± 0.002%/h to 0.044 ± 0.004%/h, and
0.023 ± 0.003%/h to 0.044 ± 0.004%/h, respectively; P < 0.001),
with no differences between groups (P > 0.05). Myofibrillar protein
synthesis rates during the late postprandial phase (2–5 h) remained
elevated in the MILK group (0.039 ± 0.004%/h; P < 0.001), but
returned to baseline values following BCAA and BCKA ingestion
(0.024 ± 0.005%/h and 0.024 ± 0.005%/h, respectively; P > 0.05).
Conclusions: Ingestion of 6 g BCAA, 6 g BCKA, and 30 g
MILK increases myofibrillar protein synthesis rates during the early
postprandial phase (0–2 h) in vivo in healthy older males. The
postprandial increase following the ingestion of 6 g BCAA and
BCKA is short-lived, with higher myofibrillar protein synthesis
rates only being maintained following the ingestion of an equivalent
amount of intact milk protein. This trial was registered at Nederlands
Trial Register (www.trialregister.nl) as NTR6047. Am J Clin Nutr
2019;110:862–872.
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Introduction
Protein ingestion strongly increases muscle protein synthesis
rates (1, 2). The postprandial increase in muscle protein synthesis
rate has been attributed to the rise in circulating amino acids (3,
4). Amino acids serve as precursors for de novo muscle protein
synthesis and can act as strong signaling molecules activating
translation initiation via the mechanistic/mammalian target of
rapamycin complex-1 (mTORC1) pathway (5, 6). Several studies
indicate that senescent muscle is less sensitive to these anabolic
properties of amino acids (7, 8). Anabolic resistance to feeding
has been reported in the elderly and in several patient popu-
lations suffering from chronic disease (9). As a consequence,
older and/or more clinically compromised patient populations
require greater amounts of protein to be consumed (7, 10–
14) or may benefit from food fortification with branched-chain
amino acids (BCAAs) (15–19) to augment postprandial muscle
protein synthesis rates. Limited data are available regarding the
muscle protein synthetic response to ingesting BCAAs (leucine,
isoleucine, and valine) only in humans. Recently, it was shown
that BCAA ingestion increases myofibrillar protein synthesis
rates during recovery from exercise in young males (20).
However, whether BCAA ingestion can increase myofibrillar
protein synthesis rates to a similar extent when compared with
the ingestion of intact protein in vivo in older males remains to be
assessed.
In many clinically compromised populations, simply increas-
ing protein intake is not realistic and has been suggested to
be unfavorable in patients with chronic kidney disease (CKD)
because of potential renal injury (21). Hence (very) low protein
diets are often prescribed in certain disease stages of patients
with CKD, further compromising their capacity to preserve
muscle mass (22–24). Supplementation with branched-chain
ketoacids (BCKAs) has been applied in these conditions as
these keto-analogs do not provide nitrogen (N) and may help
to lower nitrogen intake as BCKAs can be transaminated into
BCAAs (25, 26). BCKAs are readily available, safe for human
consumption (27), and efficiently absorbed in the small intestine
(28). However, intestinal absorption rates of BCKAs appear
to be moderately lower when compared with BCAAs (29). In
addition, oral administration of BCKAs, but not BCAAs, appears
to induce substantial first-pass oxidation in splanchnic organs
(30). Therefore, the nutritional efficiency, and thus bioavailability
of ingested BCKAs, may be considerably lower when compared
with BCAAs (26, 31). A lower bioavailability may suggest
that BCKAs do not stimulate muscle protein synthesis to a
similar extent when compared with BCAAs or intact protein.
Furthermore, it has been observed that intravenous infusion
of BCKAs does not stimulate whole-body protein synthesis
(32). However, it is important to note that whole-body protein
synthesis is not necessarily reflective of muscle protein synthesis
and evidence from animal work in fact supports a role for
BCKAs as a nutrient regulator of muscle protein synthesis
(33, 34). To date, no studies have investigated the effects of
ingesting BCKAs on muscle protein synthesis in humans. We
hypothesize that ingestion of intact protein, BCAAs, as well as




Forty-five healthy (tracer naïve) older men (age: 71 ± 1
y; BMI: 25.4 ± 0.8 kg/m2) participated in this double-
blind, parallel-group, randomized trial. The trial was conducted
between January 2017 and May 2017 at Maastricht University
Medical Centre+, in Maastricht, The Netherlands (for the consort
flow chart, please see Supplemental Figure 1). The character-
istics of the subjects are detailed in Table 1. All subjects were
informed of the purpose of the study, experimental procedures,
and possible risks before providing written consent to participate.
The procedures followed were in accordance with the ethical
standards of the Medical Ethics Committee of the Maastricht
University Medical Centre+ on human experimentation and in
accordance with the Helsinki Declaration of 1975 as revised in
October 2013. This trial was registered at www.trialregister.nl as
NTR6047.
Ethics approval and consent to participate
This study was approved by the Medical Ethical Committee
of the Maastricht University Medical Centre+, The Netherlands
(METC 16-3-035). All participants provided written informed
consent before participation.
Pretesting
Volunteers between the age of 65–80 y and with a BMI
between 18.5 and 30.0 underwent medical screening to assess
glycated hemoglobin (HbA1c), whole-body glucose tolerance
[using a 2-h oral-glucose-tolerance test (35)], blood pressure,
weight, height, and body composition (by DXA; Discovery A;
Hologic). Subjects were deemed healthy based on their responses
to a medical questionnaire and their screening results.
Study design
Subjects were randomly assigned to consume a drink contain-
ing 30 g milk protein (MILK) (ReFit MPI 85; Friesland Campina;
n = 15), 6 g BCAAs (Evonik Industries; n = 15), or 6 g
BCKAs (Myolution; Evonik Industries; n = 15). The 30 g MILK
provides ∼6 g BCAAs with a total of 2.64 g leucine, which
should theoretically induce a measurable increase in postprandial
muscle protein synthesis rates ( 36). The ratio of (keto-)leucine,
(keto-)isoleucine, and (keto-)valine in both BCAA and BCKA
drinks was 2:1:1. Hence, the BCAA and BCKA drinks provided
3 g (keto-)leucine, 1.5 g (keto-)isoleucine, and 1.5 g (keto-
)valine (total 6 g). Randomization was performed by using a
computerized random-number generator. An independent person
was responsible for random assignment and drink preparation.
Diet and physical activity
All subjects were instructed to refrain from any sort of
strenuous physical activity 3 d prior to the infusion trial and
to keep their diet as consistent as possible for 2 d prior to the
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TABLE 1 Subjects’ characteristics1
BCAA BCKA MILK P
Age, y 70 ± 1 71 ± 1 72 ± 1 0.201
Body mass, kg 78.5 ± 2.2 79.0 ± 3.2 80.7 ± 2.2 0.779
BMI, kg/m2 25.9 ± 0.9 25.4 ± 0.6 24.9 ± 0.8 0.568
Systolic BP, mmHg 138 ± 3 134 ± 4 131 ± 3 0.345
Diastolic BP, mmHg 72 ± 1 68 ± 3 66 ± 2 0.101
Fat, % 24.4 ± 1.6 24.1 ± 0.9 21.9 ± 1.6 0.297
Appendicular lean mass, kg 25.3 ± 0.8 26.1 ± 0.9 26.5 ± 0.9 0.558
Lean body mass, kg 57.2 ± 1.5 57.6 ± 2.2 60.7 ± 1.5 0.246
Fasting glucose (OGTT), mmol/L 5.2 ± 0.2 4.9 ± 0.2 5.0 ± 0.2 0.346
2-h glucose (OGTT), mmol/L 7.2 ± 0.9 5.6 ± 0.4 5.8 ± 0.6 0.103
Fasting insulin (OGTT), mU/L 10.8 ± 1.8 10.1 ± 1.7 10.0 ± 1.1 0.915
2-h insulin (OGTT), mU/L 74.0 ± 20.9 59.1 ± 19.1 39.9 ± 10.0 0.307
HbA1c, % 5.5 ± 0.2 5.5 ± 0.1 5.5 ± 0.1 0.986
HOMA2-IR 1.4 ± 0.2 1.3 ± 0.2 1.3 ± 0.2 0.913
OGIS, mL/min/m2 367 ± 21 385 ± 19 409 ± 19 0.252
1Values represent means ± SEM, n = 15 per group. Data were analyzed using a one-factor ANOVA. No differences were detected between groups.
BCAA, 6 g branched-chain amino acids; BCKA, 6 g branched-chain ketoacids; BP, blood pressure; HbA1c, glycated hemoglobin; HOMA2-IR, homeostatic
model assessment of insulin resistance; MILK, 30 g milk protein; OGIS, oral glucose insulin sensitivity; OGTT, oral-glucose-tolerance test.
subjects consumed the same standardized meal (2061 kJ/487
kcal) providing 31.8 g protein, 58.7 g carbohydrate, and 11.3 g
fat at ∼1800 h followed by an evening snack (985 kJ/234 kcal)
composed of 34.7 g protein, 18.5 g carbohydrate, and 0.0 g fat at
2200 h.
Infusion protocol
At 0800 h, after an overnight fast, subjects arrived at the
laboratory by car or public transport. A catheter was inserted
into an antecubital vein for stable isotope labeled amino acid
infusion. A second catheter was inserted into a dorsal hand
vein of the contralateral arm and placed in a hot box (60◦C)
for arterialized blood sampling (37). After obtaining a baseline
blood sample, the plasma phenylalanine pools were primed with
a single dose of l-[ring-13C6]-phenylalanine (2.25 μmol·kg−1),
after which a continuous l-[ring-13C6]-phenylalanine (0.05
μmol·kg−1·min−1) intravenous infusion was initiated (t = −180
min). Subsequently, the subjects rested in a supine position for
180 min during which 4 additional arterialized blood samples
were drawn (t = −90, −60, −30, and 0 min). A muscle biopsy
sample was then collected from the m. vastus lateralis of a
randomly chosen leg (t = 0 min). After collection of the first
muscle biopsy sample, subjects consumed a drink containing 30
g MILK (n = 15), 6 g BCAAs (n = 15), or 6 g BCKAs (n = 15)
at t = 0 min. A small amount of l-[ring-13C6]-phenylalanine
(6%) was added to the MILK beverage to prevent precursor pool
dilution. Additional arterialized blood samples were collected at
t = 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, and 300
min. Second and third muscle biopsies were collected at t = 120
min and t = 300 min to determine postprandial myofibrillar
protein synthesis rates. Blood samples were collected in EDTA-
containing tubes and centrifuged at 1000 × g for 10 min at 4◦C.
Aliquots of plasma were snap frozen in liquid nitrogen and stored
at −80◦C. Biopsy samples were collected from the middle region
of the M. vastus lateralis, ∼15 cm above the patella and 3 cm
below entry through the fascia, using the percutaneous needle
biopsy technique (38). Muscle samples were dissected carefully,
freed from any visible nonmuscle material, immediately frozen
in liquid nitrogen, and stored at −80◦C until further analysis.
For a schematic representation of the infusion protocol, see
Figure 1.
Plasma and muscle tissue analysis
Details of analysis related to the determination of plasma
(glucose, insulin, ammonia, ketoacids, amino acids, HbA1c,
l-[ring-13C6]-phenylalanine, mixed plasma proteins) as well
as muscle (myofibrillar protein l-[ring-13C6]-phenylalanine
ring-
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enrichments) data are presented in the Supplemental
Methods.
Calculations
Myofibrillar protein fractional synthetic rates (FSRs) were
calculated using the standard precursor-product equation, as
follows (39):
FSR = Ep
Eprecursor · t · 100 (1)
Ep is the increment in myofibrillar protein-bound l-[ring-13C6]-
phenylalanine enrichment after an incorporation period, Eprecursor
is the weighted mean plasma l-[ring-13C6]-phenylalanine enrich-
ment during that incorporation period, and t is the incorporation
period (h). Weighted mean plasma enrichments were calculated
by taking the average enrichment between all consecutive time
points and correcting for the time between these sampling time
points. The weighted mean plasma precursor pool is preferred in
this setting because the more frequent sampling time points allow
a more accurate correction of the transient changes in precursor
pool enrichments over time (40). For basal FSR, plasma protein
samples at t = −180 min and muscle biopsy samples at t = 0 min
were used; and for postprandial FSRs, muscle biopsy samples at
t = 0, 120, and 300 min were used.
Statistical analysis
All data are expressed as means ± SEM. Baseline char-
acteristics, incremental AUC (iAUC; for postprandial plasma
insulin and ammonia concentrations), and plasma amino acid
enrichments were compared between treatment groups using one-
factor ANOVA. For time-dependent variables, repeated-measures
ANOVA with treatment as a between-subjects factor and time
as a within-subjects factor was used (i.e., all time points for
plasma concentrations and basal compared with postprandial
for muscle data). In case of significant interactions, separate
analyses were performed within each treatment group, as well
as between treatment groups for every time period separately
(e.g., for FSR values, separate one-factor ANOVA for basal,
0–2 h, 2–5 h, and 0–5 h). In the case of significant treatment
effects, Bonferroni post hoc analyses were performed to locate
the effects. Significance was set at P < 0.05. Calculations were
performed using SPSS (version 21.0, IBM Corp.).
Results
Plasma glucose, insulin, and ammonia
Plasma glucose concentrations (Figure 2) slightly declined
over time in the BCKA and BCAA groups (P < 0.05),
whereas they slightly increased over time in the MILK group
(P < 0.05). Plasma glucose concentrations were significantly
higher between t = 90 and 210 min in the MILK group
compared with the BCAA group (P < 0.05). Plasma insulin
concentrations (Figure 3A) showed a rapid and significant
increase following beverage ingestion in the BCAA and MILK
group (P < 0.05), but not in the BCKA group. A greater increase
in plasma insulin concentrations was observed in the MILK
FIGURE 2 Plasma glucose concentrations over time after the ingestion
of 30 g milk protein (MILK; n = 15), 6 g branched-chain amino acids
(BCAA; n = 15), or 6 g branched-chain ketoacids (BCKA; n = 15) in healthy
older males. The dotted line represents the ingestion of the drink. Values
represent means + SEM. Data were analyzed with repeated measures (time
× treatment group) ANOVA and separate analyses were performed when a
significant interaction was detected. Bonferroni post hoc testing was used to
detect differences between groups. Time × treatment interaction, P < 0.001.
b, MILK significantly different (P < 0.05) from BCAA.
group compared with the BCAA group between t = 75 and
120 min (P < 0.05). In agreement, the iAUC above fasting
plasma insulin concentrations was significantly greater in the
MILK group compared with the BCKA and BCAA groups
(P < 0.05; Figure 3B). The iAUC of plasma ammonia
(Figure 4) did not show significant differences between groups,
despite the fact that plasma ammonia concentrations were
substantially reduced during the postprandial period in the
BCKA group.
Plasma amino acids
Plasma phenylalanine (Figure 5A), leucine (Figure 5B),
isoleucine (Figure 5C), and valine (Figure 5D) concentrations
over time are depicted in Figure 5. Significant time × treatment
interactions were observed for plasma phenylalanine, leucine,
isoleucine, and valine concentrations (P < 0.001). Following
drink ingestion, a rapid increase in plasma phenylalanine
concentrations was found in the MILK group (P < 0.05), whereas
plasma phenylalanine concentrations remained unchanged and
decreased over time in the BCKA and BCAA groups, respectively
(P < 0.05). Plasma leucine concentrations increased significantly
after drink ingestion in all groups (P < 0.01), with the highest
peak plasma leucine concentrations measured in the BCAA
group (P < 0.05). Plasma isoleucine and valine concentrations
increased significantly after drink ingestion and remained
elevated for the entire postprandial period in the BCAA and
MILK groups (P < 0.01), whereas no changes were observed in
the BCKA group.
Plasma BCAA (Figure 6A), essential amino acid (EAA;
Figure 6B), nonessential amino acid (NEAA-glutamine;
Figure 6C), and total amino acid (TAA; Figure 6D)
concentrations over time are depicted in Figure 6. For BCAA,
EAA, NEAA, and TAA concentrations, significant time ×






/ajcn/article-abstract/110/4/862/5524534 by Australian C
atholic U
niversity user on 30 Septem
ber 2019
866 Fuchs et al.
FIGURE 3 Plasma insulin concentrations over time (A) and total insulin
responses, expressed as incremental AUC (B) after the ingestion of 30 g
milk protein (MILK; n = 15), 6 g branched-chain amino acids (BCAA;
n = 15), or 6 g branched-chain ketoacids (BCKA; n = 15) in healthy older
males. The dotted line represents the ingestion of the drink. Values represent
means + SEM. Data in panel A were analyzed using repeated measures (time
× treatment group) ANOVA and separate analyses were performed when a
significant interaction was detected. Bonferroni post hoc testing was used to
detect differences between groups. Time × treatment interaction, P < 0.001.
a, MILK significantly different (P < 0.05) from BCKA; b, MILK significantly
different (P < 0.05) from BCAA. Data in panel B were analyzed using a one-
factor ANOVA with Bonferroni correction. #Significantly different (P < 0.05)
from BCAA and BCKA.
total BCAA concentrations increased significantly after drink
ingestion and remained elevated for the entire postprandial
period in the BCAA and MILK groups (P < 0.001). For
the BCKA group, plasma total BCAA concentrations were
only significantly higher than fasting values at t = 150 and
300 min (P < 0.01). Plasma EAA concentrations increased
significantly after drink ingestion and remained elevated for the
entire postprandial period in the BCAA (apart from t = 240
min; P > 0.05) and MILK groups (P < 0.05), whereas no
increase was found after BCKA ingestion. Plasma total NEAA
concentrations following drink ingestion significantly increased
and remained elevated until t = 240 min after MILK ingestion
(P < 0.001), did not change after BCKA ingestion, and were
significantly lower when compared to fasting values at t = 90,
180, 210, and 300 min in the BCAA group (P < 0.05). Plasma
TAA concentrations immediately increased after BCAA (until
t = 120 min; P < 0.001) and MILK ingestion (remained elevated
FIGURE 4 Plasma total ammonia concentrations, expressed as incre-
mental AUC after the ingestion of 30 g milk protein (MILK; n = 15),
6 g branched-chain amino acids (BCAA; n = 15), or 6 g branched-
chain ketoacids (BCKA; n = 15) in healthy older males. Values represent
means ± SEM. Data were analyzed using a one-factor ANOVA. No
significant differences between treatments (P > 0.05).
for the entire postprandial period; P < 0.01). No significant
changes were observed after BCKA ingestion.
Plasma α-ketoacids
Plasma α-ketoisocaproic acid (KIC; the α-ketoacid of
leucine; Figure 7A), α-keto-β-methylvalerate (KMV; the α-
ketoacid of isoleucine; Figure 7B), α-ketoisovalerate (KIV; the
α-ketoacid of valine; Figure 7C), and total BCKA (Figure 7D)
concentrations over time are depicted in Figure 7. Significant
time × treatment interactions were observed for plasma KIC,
KMV, KIV, and total BCKA concentrations (P < 0.001).
Following drink ingestion, plasma KIC and KMV concentrations
significantly increased and remained elevated for the entire
postprandial period in the BCKA (P < 0.001, apart from
t = 240 min for KMV) and BCAA groups (from t = 30 min;
P < 0.05). For the MILK group, KIC concentrations were
only significantly higher than fasting values between t = 150–
300 min and KMV concentrations were only significantly
higher than fasting values between t = 75–210 min and at
t = 300 min (P < 0.05). Following drink ingestion, plasma KIV
concentrations significantly increased in the BCKA group (from
t = 15 until t = 150 min; P < 0.01), whereas no changes were
observed in the BCAA and MILK groups. Plasma total BCKA
concentrations increased significantly after drink ingestion for the
entire postprandial period in the BCKA (P < 0.001) and BCAA
groups (P < 0.001; apart from t = 15 min), whereas they were
only significantly increased between t = 90–300 min in the MILK
group (P < 0.05).
Isotope tracer analysis
Prior to BCAA, BCKA, or MILK ingestion plasma l-[ring-
13C6]-phenylalanine enrichments averaged 7.5 ± 0.3, 7.4 ± 0.1,
and 7.4 ± 0.2 mole % excess (MPE), respectively, with no
differences between treatments (data not shown). Plasma l-[ring-
13C6]-phenylalanine enrichments during the postprandial period
averaged 8.7 ± 0.3, 7.9 ± 0.2, and 7.3 ± 0.2 MPE for the
BCAA, BCKA, and MILK groups respectively, with significant
differences between the BCAA and BCKA groups (P < 0.01) as
well as the BCAA and MILK groups (P < 0.001), but not between
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FIGURE 5 Plasma phenylalanine (A), leucine (B), isoleucine (C), and valine (D) concentrations over time after the ingestion of 30 g milk protein (MILK;
n = 15), 6 g branched-chain amino acids (BCAA; n = 15), or 6 g branched-chain ketoacids (BCKA; n = 15) in healthy older males. The dotted line represents the
ingestion of the drink. Values represent means + SEM. Data were analyzed with repeated measures (time × treatment group) ANOVA and separate analyses
were performed when a significant interaction was detected. Bonferroni post hoc testing was used to detect differences between groups. Time × treatment
interaction, P < 0.001. a, MILK significantly different (P < 0.05) from BCKA; b, MILK significantly different (P < 0.05) from BCAA; c, BCAA significantly
different (P < 0.05) from BCKA.
Myofibrillar protein synthesis rates calculated based on the
plasma precursor pool are depicted in Figure 8. No differences
were observed in basal muscle protein synthesis rates between
groups (P = 0.624). Myofibrillar protein synthesis rates increased
from basal to the early (0–2 h) postprandial period in all
groups (from 0.020 ± 0.002%/h to 0.042 ± 0.004%/h in the
MILK group, 0.022 ± 0.002%/h to 0.044 ± 0.004%/h in the
BCAA group, and 0.023 ± 0.003%/h to 0.044 ± 0.004%/h
in the BCKA group; P < 0.001), with no differences between
treatment groups (time × treatment interaction: P = 0.969, main
treatment effect: P = 0.732). A significant time × treatment
interaction (P = 0.002) showed that after ingestion of MILK,
myofibrillar protein synthesis rates remained elevated over the
2–5 h postprandial period when compared with basal protein
synthesis rates (from 0.020 ± 0.002%/h to 0.039 ± 0.004%/h;
P < 0.001). In the BCKA and BCAA groups, myofibrillar protein
synthesis rates decreased back to basal rates during the 2–5 h
postprandial period (0.024 ± 0.005%/h and 0.024 ± 0.005%/h,
respectively; P > 0.05). During the late (2–5 h) postprandial
period, myofibrillar protein synthesis rates were higher in the
MILK group when compared with the BCAA (P = 0.023) and
BCKA groups (P = 0.023). A significant time × treatment
interaction was also observed when comparing basal myofibrillar
protein synthesis rates with the entire 5-h postprandial period
(P = 0.003). Over the entire 5-h postprandial period (0–
5 h), myofibrillar protein synthesis rates were significantly
elevated above basal for all treatments (P < 0.005), but were
significantly higher in the MILK group (0.040 ± 0.002%/h)
compared with the BCKA (0.032 ± 0.003%/h; P = 0.023)
and BCAA groups (0.032 ± 0.003%/h; P = 0.019), with no
significant differences between the BCKA and BCAA groups
(P > 0.05).
Discussion
The present study demonstrated that ingestion of BCAAs,
BCKAs, and MILK (providing an equivalent amount of BCAAs)
significantly increased myofibrillar protein synthesis rates during
the early (0–2 h) postprandial phase, with no differences
observed between treatments. In the late (2–5 h) postprandial
period myofibrillar protein synthesis rates remained elevated
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FIGURE 6 Plasma branched-chain amino acids (BCAA; A), essential amino acid (EAA; B), nonessential amino acid (NEAA-glutamine; C), and total
amino acid (TAA-glutamine; D) concentrations over time after the ingestion of 30 g milk protein (MILK; n = 15), 6 g BCAA (n = 15), or 6 g branched-chain
ketoacids (BCKA; n = 15) in healthy older males. The dotted line represents the ingestion of the drink. Values represent means + SEM. Data were analyzed
with repeated measures (time × treatment group) ANOVA and separate analyses were performed when a significant interaction was detected. Bonferroni post
hoc testing was used to detect differences between groups. Time × treatment interaction, P < 0.001. a, MILK significantly different (P < 0.05) from BCKA;
b, MILK significantly different (P < 0.05) from BCAA; c, BCAA significantly different (P < 0.05) from BCKA.
rates following BCAA and BCKA ingestion returning to baseline
values.
It has been well established that ingestion of dietary protein
strongly increases muscle protein synthesis rates (1, 2, 41).
The postprandial increase in muscle protein synthesis rates
has been attributed to the postprandial release of (essential)
amino acids (3, 4, 42, 43), with the rise in circulating BCAAs
and especially leucine being of particular relevance (16, 44–
47). In line with previous work (10, 48, 49), we show a
rapid postprandial increase in plasma (essential) amino acid
concentrations following the ingestion of 30 g MILK, with
plasma leucine concentrations reaching 294 ± 12 μmol/L within
30 min (Figure 5B). The postprandial rise in plasma amino
acid availability resulted in a 111% increase in myofibrillar
protein synthesis rates within the first 2 h after protein ingestion
when compared with basal, postabsorptive myofibrillar protein
synthesis rates (from 0.020 ± 0.002 to 0.042 ± 0.004%/h; Figure
8). In addition, postprandial myofibrillar protein synthesis rates
assessed during the entire 5-h postprandial period were also
higher following MILK ingestion when compared with baseline
values (0.040 ± 0.002 compared with 0.020 ± 0.002%/h,
respectively).
As the postprandial increase in muscle protein synthesis has
been attributed largely to the postprandial increase in plasma
BCAAs, we also assessed the impact of ingesting BCAAs
only. Following ingestion of 6 g BCAAs, which equals the
amount of BCAAs present in 30 g MILK, we observed a rapid
rise in circulating BCAAs (Figure 6A), with plasma leucine
concentrations reaching 2–3 fold higher concentrations when
compared with MILK ingestion (Figure 5B). We also observed a
strong, significant increase in myofibrillar protein synthesis rates
within the first 2 h after BCAA ingestion (from 0.022 ± 0.002
to 0.044 ± 0.004%/h; Figure 8). This seems to be in line
with previous work showing an increase in myofibrillar protein
synthesis rate during a 2.5-h period after ingesting 3.4 g of
free leucine (50). The rapid and marked increase in plasma
BCAA availability after BCAA ingestion may have exceeded
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FIGURE 7 Plasma α-ketoisocaproic acid (KIC; the α-ketoacid of leucine; A), α-keto-β-methylvalerate (KMV; the α-ketoacid of isoleucine; B), α-
ketoisovalerate (KIV; the α-ketoacid of valine; C), and branched-chain ketoacid (BCKA) (D) concentrations over time after the ingestion of 30 g milk protein
(MILK; n = 15), 6 g branched-chain amino acids (BCAA; n = 15), or 6 g BCKA (n = 15) in healthy older males. The dotted line represents the ingestion of the
drink. Values represent means + SEM. Data were analyzed with repeated measures (time × treatment group) ANOVA and separate analyses were performed
when a significant interaction was detected. Bonferroni post hoc testing was used to detect differences between groups. Time × treatment interaction, P < 0.001.
a, MILK significantly different (P < 0.05) from BCKA; b, MILK significantly different (P < 0.05) from BCAA; c, BCAA significantly different (P < 0.05)
from BCKA.
so that during the 2-h postprandial period myofibrillar protein
synthesis rates did not differ after ingestion of BCAA or MILK.
Though this would be in line with the proposed muscle full effect
(51, 52), these high myofibrillar protein synthesis rates could not
be maintained following BCAA as opposed to MILK ingestion
during the latter stages (2–5 h) of the postprandial period (Figure
8). These data suggest that besides the postprandial rise in plasma
BCAA concentrations, other (essential) amino acids need to
be provided to allow a more prolonged postprandial increase
in muscle protein synthesis rate (53). Though the postprandial
rise in muscle protein synthesis rate following protein ingestion
can be initiated by the increased BCAA availability, it may be
maintained only when sufficient other (essential) amino acids
are provided to serve as precursors for de novo muscle protein
synthesis. Alternatively, it could be speculated that ingestion of
greater amounts (> 6 g) and/or a more sustained provision of
BCAA are needed to prolong the elevation in muscle protein
synthesis rates.
BCKAs are ketoanalogs of the 3 BCAAs and play an active
role in BCAA metabolism, due to their rapid in vivo inter-
convertibility (by transamination) (26). As the transamination
capacity is high in skeletal muscle (54), when BCKAs are
transaminated into BCAAs, they may directly stimulate muscle
protein synthesis. It has previously been shown that infusion
with the BCKA α-ketoisocaproic acid stimulates muscle protein
synthesis in neonatal pigs (33). However, the effect of BCKA
ingestion on muscle protein synthesis rates in humans has never
been assessed. Ingestion of 6 g BCKA, which was tolerated
well in all subjects with no reported side effects, resulted in
a strong postprandial increase in plasma BCKA concentrations
(Figure 7). Concomitantly, we also observed a small but
significant increase in plasma leucine concentrations (Figure 5B),
suggesting that there is some, albeit limited, conversion of KIC
to leucine in vivo in healthy humans. Despite only minimal
changes in plasma BCAA or other amino acid concentrations
following BCKA ingestion (Figure 6), we observed a rapid
increase in myofibrillar protein synthesis rates during the early
postprandial phase that did not differ from the early postprandial
response following BCAA or MILK ingestion (Figure 8).
However, similar to the postprandial response observed following
BCAA ingestion, these elevated myofibrillar protein synthesis
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FIGURE 8 Myofibrillar protein fractional synthetic rates (FSR; in %/h)
during the fasting state (basal) and over the early (0–2 h), late (2–5 h), and
entire (0–5 h) postprandial period after the ingestion of 30 g milk protein
(MILK; n = 15), 6 g branched-chain amino acids (BCAA; n = 15), or 6 g
branched-chain ketoacids (BCKA; n = 15) in healthy older males. Values
represent means + SEM. Data were analyzed with repeated measures (time
× treatment group) ANOVA and separate analyses were performed when a
significant interaction was detected. Bonferroni post hoc testing was used to
detect differences between groups. ∗Significantly different (P < 0.01) from
basal; #significantly different (P < 0.05) from BCAA and BCKA.
(2–5 h). The observation that BCKA ingestion strongly increases
(early) postprandial myofibrillar protein synthesis rates, despite
a minimal rise in circulating plasma leucine concentrations,
implies that either BCKA-derived BCAA (by transamination)
are directly used within muscle to stimulate muscle protein
synthesis or that alternative metabolites may be involved in the
early postprandial stimulation of muscle protein synthesis. It
has previously been shown that leucine metabolites, such as
β-hydroxy-β-methylbutyrate, can stimulate myofibrillar protein
synthesis (50, 55). In contrast to the ketoanalog of leucine,
β-hydroxy-β-methylbutyrate cannot be converted back into
leucine. In line with the minimal increase in plasma leucine
concentrations following BCKA ingestion, our findings suggest
that the stimulatory effect of BCKA ingestion on myofibrillar
protein synthesis may work directly (KIC) and/or indirectly
via conversion to β-hydroxy-β-methylbutyrate. Clearly, research
is warranted to elucidate alternative metabolites and pathways
that could be (at least partially) responsible for the stimulatory
effect of BCKA ingestion on muscle protein synthesis. This
will also yield important information on whether the anabolic
properties of BCKA and BCAA involve separate pathways and,
as such, may be combined to further increase postprandial
muscle protein synthesis rates. Ultimately, net muscle protein
accretion is determined by the balance between muscle protein
synthesis and breakdown rates and it has been suggested that
BCKA, with KIC in particular, has a profound impact on muscle
protein breakdown. It appears that KIC, and not leucine per
se, is primarily responsible for the inhibitory effect on muscle
protein breakdown (56–59). This further supports the potential
of BCKAs as an anabolic agent to stimulate muscle protein
accretion.
BCKAs lack an amino group bound to the α-carbon in their
molecular structure and, therefore, do not provide nitrogen.
In support, transamination of the BCKAs into their respective
BCAAs was likely responsible for the observed decline in plasma
ammonia concentrations (Figure 4). The potential therapeutic
value of BCKAs has been studied in several diseases and
disorders, but appears particularly relevant for patients with
CKD (25, 26). Patients with CKD are advised to adhere to
low protein diets during certain stages of their disease (60),
restricting them in their capacity to maintain muscle mass.
The observed stimulatory effect of BCKA ingestion on early
postprandial myofibrillar protein synthesis rates can be of
particular relevance for this patient group as it may support
them in preventing or attenuating the progressive loss of muscle
mass without increasing nitrogen intake (34, 61). Furthermore,
there are suggestions that a low protein diet improves the
nutritional efficiency of BCKAs (26, 62). Therefore, future
studies should look into the benefits of BCKA co-ingestion to
stimulate postprandial muscle protein synthesis rates in patients
with CKD ingesting a diet relatively low in dietary protein
content.
In conclusion, ingestion of 6 g BCAAs, 6 g BCKAs, and
30 g MILK increases myofibrillar protein synthesis rates during
the early postprandial phase (0–2 h) in vivo in healthy older
males. The postprandial increase following the ingestion of 6
g BCAAs and BCKAs is short-lived, with higher myofibrillar
protein synthesis rates only being maintained following the
ingestion of an equivalent amount of intact milk protein.
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